SCHEMBL25402001

SCHEMBL25402001

CCCCOC(=O)C(C)n1ccnc1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP19A1 P11511 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
NPSR1 Q6W5P4 2/20 0.42
LMNA P02545 2/20 0.42
FPR2 P25090 1/20 0.41
L3MBTL1 Q9Y468 4/20 0.41
ALDH1A1 P00352 4/20 0.41
POLB P06746 1/20 0.41
KMT2A Q03164 1/20 0.41
AGTR2 P50052 1/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
HPGD P15428 1/20 0.39
ALPG P10696 1/20 0.36
PPARG P37231 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25403046 0.94 LMNA (0.40) CYP1A2CYP3A4CYP2D6CYP19A1CYP2C9
SCHEMBL2970104 0.86 FPR2 (0.51) CYP1A2CYP2C9CYP2C19NPSR1LMNA
SCHEMBL25404385 0.82 NPSR1 (0.47) CYP3A4NPSR1LMNAFPR2L3MBTL1
SCHEMBL2962693 0.79 CYP26A1 (0.42) NPSR1FPR2ALDH1A1POLBNPC1
SCHEMBL25403319 0.77 MAPT (0.46) CYP3A4NPSR1LMNAL3MBTL1ALDH1A1
SCHEMBL25400901 0.74 ALDH1A1 (0.38) CYP1A2CYP3A4CYP2D6CYP19A1CYP2C9
SCHEMBL10688674 0.73 ALDH1A1 (0.44) FPR2ALDH1A1SMN1; SMN2
SCHEMBL9806401 0.72 FPR2 (0.56) CYP1A2CYP2C9CYP2C19NPSR1LMNA
SCHEMBL25400633 0.72 LMNA (0.40) CYP1A2CYP19A1CYP2C19NPSR1LMNA
SCHEMBL28789383 0.71 TBXA2R (0.44) CYP1A2CYP3A4CYP2D6CYP19A1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025079509-A1 COMPOUND, COMPOSITION, CURED PRODUCT, AND METHOD FOR PRODUCING CURED PRODUCT 株式会社ADEKA 2025-04-17 WO disclosed
US-20240409681-A1 CLATHRATE COMPOUND, EPOXY RESIN CURING AGENT, AND CURABLE RESIN COMPOSITION ADEKA CORPORATION (JP) 2024-12-12 US disclosed
US-20240317967-A1 CURABLE RESIN COMPOSITION ADEKA CORPORATION (JP) 2024-09-26 US disclosed
EP-4424673-A1 CLATHRATE COMPOUND, EPOXY RESIN CURING AGENT, AND CURABLE RESIN COMPOSITION ADEKA CORPORATION (JP) 2024-09-04 EP disclosed
CN-118369320-A Compound, curable resin composition, and cured product 株式会社艾迪科 2024-07-19 CN disclosed
CN-118076588-A Inclusion compound, epoxy resin curing agent, and curable resin composition 株式会社艾迪科 2024-05-24 CN disclosed
US-20240109869-A1 CHARGE TRANSFER COMPLEX ADEKA CORPORATION (JP) 2024-04-04 US disclosed
US-20240084065-A1 NOVEL COMPOUND, AND CURABLE RESIN COMPOSITION CONTAINING SAID COMPOUND ADEKA CORPORATION (JP) 2024-03-14 US disclosed
EP-4289883-A1 CURABLE RESIN COMPOSITION ADEKA CORPORATION (JP) 2023-12-13 EP disclosed
EP-4289837-A1 NOVEL COMPOUND, AND CURABLE RESIN COMPOSITION CONTAINING SAID COMPOUND ADEKA CORPORATION (JP) 2023-12-13 EP disclosed
EP-4289821-A1 CHARGE TRANSFER COMPLEX Adeka Corporation (JP) 2023-12-13 EP disclosed
CN-116848105-A Novel compound and curable resin composition containing same 株式会社艾迪科 2023-10-03 CN disclosed
WO-2023176703-A1 COMPOUND, CURABLE RESIN COMPOSITION AND CURED PRODUCT 株式会社ADEKA 2023-09-21 WO disclosed
CN-116783230-A Curable resin composition 株式会社艾迪科 2023-09-19 CN disclosed
CN-116710436-A Charge transfer complexes 株式会社艾迪科 2023-09-05 CN disclosed
WO-2023074450-A1 CLATHRATE COMPOUND, EPOXY RESIN CURING AGENT, AND CURABLE RESIN COMPOSITION 株式会社ADEKA 2023-05-04 WO disclosed
WO-2022168670-A1 CHARGE TRANSFER COMPLEX 株式会社ADEKA 2022-08-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109869-A1 CHARGE TRANSFER COMPLEX TRMT1, ELP1, SEM1 CYP1A2 3955/4885CYP3A4 2749/4885CYP2D6 3392/4885
US-20240084065-A1 NOVEL COMPOUND, AND CURABLE RESIN COMPOSITION CONTAINING SAID COMPOUND PSMC6, CAND1, RBX1 CYP1A2 2363/4885CYP3A4 2489/4885CYP2D6 2711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.